The three RAS genes—HRAS, NRAS and KRAS—are collectively mutated in one-third of
human cancers, where they act as prototypic oncogenes. Interestingly, there are rather …

Lung cancer is a complex disease composed of diverse histological and molecular types
with clinical relevance. The advent of large-scale molecular profiling has been helpful to …

Allosteric kinase inhibitors offer a potentially complementary therapeutic strategy to ATP-
competitive kinase inhibitors due to their distinct sites of target binding. In this study, we …

Single-cell RNA sequencing (scRNA-seq) has emerged as a powerful tool for resolving
transcriptional heterogeneity. However, its application to studying cancerous tissues is …

Purpose: Activation of MET oncogene as the result of amplification or activation mutation
represents an emerging molecular target for cancer treatment. We comprehensively studied …

Assessment of KRAS status is mandatory in patients with metastatic colorectal cancer
(mCRC) before applying targeted therapy. We describe here a blinded prospective study to …

Objective To establish evidence-based recommendations for the molecular analysis of lung
cancers that are that are required to guide EGFR-and ALK-directed therapies, addressing …

Introduction EGFR exon 20 insertions (EGFRex20ins) comprise an uncommon subset of
EGFR-activating alterations relatively insensitive to first-and second-generation EGFR …

Activating mutations in KRAS occur in 30% to 40% of colorectal cancers. How mutant KRAS
alters cancer cell behavior has been studied intensively, but non-cell autonomous effects of …

Molecular heterogeneity is a frequent event in cancer responsible of several critical issues in
diagnosis and treatment of oncologic patients. Lung tumours are characterized by high …